Pharmacokinetics and Pharmacodynamics of Edoxaban Before and After Bariatric Surgery

NCT06326138 | Withdrawn Phase 1

• 1 other identifier: 22121
• Study Type: interventional
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

The study will be conducted at a single site in the Canada, Quebec. Participants will be recruited from the bariatric surgery clinic and will be required to be either, waiting for sleeve gastrectomy surgery (n=12, restrictive bariatric surgery, Group 1) or Roux-en-Y gastric bypass (n=12, mixed bariatric surgery, Group 1), or had underwent Roux-en-Y gastric bypass 12 ± 3 months ago (n=12, Group 2). Participants in Group 1, edoxaban pharmacokinetic and pharmacodynamics will be evaluated before and 48 ± 5 hours after bariatric surgery (sleeve gastrectomy and Roux-en-Y gastric bypass). Participants in Group 2, edoxaban pharmacokinetic and pharmacodynamics will be evaluated only once, at 12 ± 3 months following their Roux-en-Y gastric bypass. All participants will be received single oral doses of 60 mg edoxaban at each pharmacokinetic and pharmacodynamics evaluation.

Conditions

Bariatric Surgery Candidate

Outcome Measures

Primary Outcomes (4)

• Pharmacokinetics edoxaban parameter

  Maximum edoxaban plasma concentration

  0 hour (before taking edoxaban) - 0.5 hours - 1 hour - 1.5 hours - 2 hours - 2.5 hours - 3 hours - 4 hours - 6 hours - 8 hours - 12 hours - and 24 hours after taking edoxaban

• Pharmacokinetics edoxaban parameter

  Time to reach maximum edoxaban plasma concentration

  0 hour (before taking edoxaban) - 0.5 hours - 1 hour - 1.5 hours - 2 hours - 2.5 hours - 3 hours - 4 hours - 6 hours - 8 hours - 12 hours - and 24 hours after taking edoxaban

• Pharmacokinetics edoxaban parameter

  Area under the edoxaban plasma concentration-time curve

  0 hour (before taking edoxaban) - 0.5 hours - 1 hour - 1.5 hours - 2 hours - 2.5 hours - 3 hours - 4 hours - 6 hours - 8 hours - 12 hours - and 24 hours after taking edoxaban

• Pharmacokinetics edoxaban parameter

  Edoxaban half time

  0 hour (before taking edoxaban) - 0.5 hours - 1 hour - 1.5 hours - 2 hours - 2.5 hours - 3 hours - 4 hours - 6 hours - 8 hours - 12 hours - and 24 hours after taking edoxaban

Secondary Outcomes (3)

• Pharmacodynamics edoxaban parameter

  0 hour (before taking edoxaban) - 0.5 hours - 1 hour - 1.5 hours - 2 hours - 2.5 hours - 3 hours - 4 hours - 6 hours - 8 hours - 12 hours - and 24 hours after taking edoxaban

• Pharmacodynamics edoxaban parameter

  0 hour (before taking edoxaban) - 0.5 hours - 1 hour - 1.5 hours - 2 hours - 2.5 hours - 3 hours - 4 hours - 6 hours - 8 hours - 12 hours - and 24 hours after taking edoxaban

• Pharmacodynamics edoxaban parameter

  0 hour (before taking edoxaban) - 0.5 hours - 1 hour - 1.5 hours - 2 hours - 2.5 hours - 3 hours - 4 hours - 6 hours - 8 hours - 12 hours - and 24 hours after taking edoxaban

Study Arms (2)

Group 1 - Roux en Y gastric bypass and Sleeve Gastrectomy

EXPERIMENTAL

Edoxaban pharmacodynamic and pharmacokinetic will be evaluated before and 48 ± 5 hours after bariatric surgery (sleeve gastrectomy and Roux-en-Y gastric bypass).

Drug: Edoxaban Pharmacokinetics and Pharmacodynamics

Group 2 - Roux en Y gastric bypass

EXPERIMENTAL

Edoxaban pharmacodynamic and pharmacokinetic will be evaluated at 12 ± 3 months following Roux-en-Y gastric bypass surgery.

Drug: Edoxaban Pharmacokinetics and Pharmacodynamics

Interventions

Edoxaban Pharmacokinetics and Pharmacodynamics DRUG

Participants will be received single oral doses of edoxaban 60 mg.

Group 1 - Roux en Y gastric bypass and Sleeve Gastrectomy; Group 2 - Roux en Y gastric bypass

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male and female subjects over 18 years of age.
• Females who are of non-childbearing potential must be:
• Surgically sterile (i.e., bilateral tubal ligation or removal of both ovaries and/or uterus at least 6 months prior to dosing).
• Naturally postmenopausal (spontaneous cessation of menses) for at least 12 consecutive months prior to screening visit, with a follicle stimulating hormone level in the postmenopausal range.
• Females of childbearing potential must have a negative urine pregnancy test at each study visit with PK and PD evaluation.
• Subjects must agree not to donate blood, plasma, platelets, or any other blood components for 4 weeks before each study visit with PK and PD evaluation.
• Subjects must agree to food and drug restrictions during the study.
• Subjects must agree to abstain from alcohol, cola, tea, coffee, chocolate, and other caffeinated drink and food from 2 days before each study visit with PK and PD evaluation.
• Subjects must agree to abstain from food and beverages containing grapefruit, grapefruit juice, cranberry juice, lime, pomelo, marmalade and Seville oranges from 10 days before each study visit with PK and PD evaluation.
• Absence of clinically significant deviations from medical history, physical examination and 12-lead ECG, as deemed by the Investigator, prior to enrollment.
• Subject must have sinus rhythm on the 12-lead ECG at each study visit with PK and PD evaluation.
• Has given written informed consent prior to participating in the study.
• Able to understand and willing to comply with all study requirements, and willing to allow the collection of all blood specimens.
• Normal coagulation values from INR (\< 1.2).

You may not qualify if:

• History or current evidence of clinically significant cardiac, hepatic, renal, pulmonary, endocrine, neurologic, infectious, gastrointestinal, hematologic, or oncologic disease as determined by screening medical history, physical examination, or 12-lead ECG.
• Subjects with QTcF interval duration \> 450 msec for males and \>470 for females.
• Subjects with abnormal waveform morphology on any of the ECGs at the screening that would preclude accurate measurement of the QT interval duration.
• Subjects with a resting systolic (treated) blood pressure \> 159 mmHg or \< 90 mmHg or a diastolic blood pressure \> 95 mmHg or \< 50 mmHg.
• History of malignancy.
• Subjects who have had a clinically significant illness within 4 weeks prior to the first dose.
• Subjects who have used any drugs or substances known to be strong inhibitors or strong inducers of CYP 3A4/5 enzymes or P-gp within 28 days prior to the first dosing.
• Subjects with history of major bleeding, major trauma, or major surgical procedure of any type within 6 months of dosing.
• Subjects with history of peptic ulcer, gastrointestinal bleeding (including hematemesis, melena, rectal bleeding) or bleeding from hemorrhoids.
• Subjects with history of thrombophlebitis or pulmonary embolism.
• Subjects with history of minor bleeding episodes such as epistaxis, rectal bleeding (spots of blood on toilet paper), and gingival bleeding within 3 months before the first dose.
• Subjects who have any family history (suspected or documented) of coagulopathy.
• Females with a history of dysfunctional uterine bleeding, including history of menorrhagia (heavy menstrual bleeding), metrorrhagia, or polymenorrhea.
• Subjects with eye surgeries or trauma to the head or eye within 14 days of the first dose.
• Subjects who have used fish oil, acetylsalicylic acid, any over-the-counter medication containing acetylsalicylic acid, nonsteroidal anti-inflammatory drugs (NSAIDs), or other supplements (e.g., gingko biloba, …) that could prolong bleeding within 14 days of the first dose or expect to use these during the study.

Sponsors & Collaborators

• Institut universitaire de cardiologie et de pneumologie de Québec, University Laval: lead

Study Officials

• Paul Poirier, MD, Phd

  Institut universitaire de cardiologie et de pneumologie de Québec, University Laval

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD, PhD

Model Details: Group 1: 12 patients waiting for a sleeve gastrectomy surgery and 12 patients waiting for a Roux-en-Y gastric bypass surgery. Group 2: 12 patients 12 months after Roux-en-Y gastric bypass surgery.

Study Record Dates

• First Submitted: March 11, 2024
• First Posted: March 22, 2024
• Study Start: March 11, 2024
• Primary Completion: March 11, 2024
• Study Completion: March 11, 2024
• Last Updated: March 22, 2024

Record last verified: 2024-03

Data Sharing

• IPD Sharing: Will not share